Abstract

Science driven therapeutics addresses only the diseases but does not provide cure and sometimes fails to meet the needs of patient. The pharmaceutical companies have, in recent years, started providing complementary products to improve the therapeutic value of the medicines. This is in the form of Fixed dose combination drugs (FDCs) The last couple of years have seen a trend in marketing of FDCs by pharmaceutical companies. Common focus of FDCs include anti-infectives, CNS, cardiovascular including hypertension and lipidemia, diabetes,contraceptives, HIV and respiratory. The United States Food and Drugs Administration (USFDA) have approved FDCs to treat various conditions such as hypertension, tuberculosis, AIDS and diabetes to name a few. The pharmaceutical companies developing these FDCs protect the products from their competitors with the help of patents. Patents are a form of intellectual property, which are legal and institutional mechanisms to protect creations of mind. In recent years, there are instances of patents granted for FDCs by the USFDA. This study attempts to review issue of anti-diabetic FDCs and patents.

Original languageEnglish
Pages (from-to)12-16
Number of pages5
JournalPharma Times
Volume50
Issue number1
Publication statusPublished - 01-01-2018

Fingerprint

Patents
Hypoglycemic Agents
United States Food and Drug Administration
Pharmaceutical Preparations
Intellectual Property
Hypertension
Drug Combinations
Contraceptive Agents
Hyperlipidemias
Marketing
Names
Acquired Immunodeficiency Syndrome
Tuberculosis
HIV
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{fabf87a015c94d03bfa1a6d822db530b,
title = "Antidiabetic fixed dose combinations - Patent review",
abstract = "Science driven therapeutics addresses only the diseases but does not provide cure and sometimes fails to meet the needs of patient. The pharmaceutical companies have, in recent years, started providing complementary products to improve the therapeutic value of the medicines. This is in the form of Fixed dose combination drugs (FDCs) The last couple of years have seen a trend in marketing of FDCs by pharmaceutical companies. Common focus of FDCs include anti-infectives, CNS, cardiovascular including hypertension and lipidemia, diabetes,contraceptives, HIV and respiratory. The United States Food and Drugs Administration (USFDA) have approved FDCs to treat various conditions such as hypertension, tuberculosis, AIDS and diabetes to name a few. The pharmaceutical companies developing these FDCs protect the products from their competitors with the help of patents. Patents are a form of intellectual property, which are legal and institutional mechanisms to protect creations of mind. In recent years, there are instances of patents granted for FDCs by the USFDA. This study attempts to review issue of anti-diabetic FDCs and patents.",
author = "Janodia, {Manthan D.} and Amit Patel and Ligade, {Virendra S.} and Prashant Musmade and Muragundi, {Pradeep M.} and N. Udupa and D. Sreedhar",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "50",
pages = "12--16",
journal = "Pharma Times",
issn = "0031-6849",
publisher = "Indian Pharmaceutical Association",
number = "1",

}

Antidiabetic fixed dose combinations - Patent review. / Janodia, Manthan D.; Patel, Amit; Ligade, Virendra S.; Musmade, Prashant; Muragundi, Pradeep M.; Udupa, N.; Sreedhar, D.

In: Pharma Times, Vol. 50, No. 1, 01.01.2018, p. 12-16.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antidiabetic fixed dose combinations - Patent review

AU - Janodia, Manthan D.

AU - Patel, Amit

AU - Ligade, Virendra S.

AU - Musmade, Prashant

AU - Muragundi, Pradeep M.

AU - Udupa, N.

AU - Sreedhar, D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Science driven therapeutics addresses only the diseases but does not provide cure and sometimes fails to meet the needs of patient. The pharmaceutical companies have, in recent years, started providing complementary products to improve the therapeutic value of the medicines. This is in the form of Fixed dose combination drugs (FDCs) The last couple of years have seen a trend in marketing of FDCs by pharmaceutical companies. Common focus of FDCs include anti-infectives, CNS, cardiovascular including hypertension and lipidemia, diabetes,contraceptives, HIV and respiratory. The United States Food and Drugs Administration (USFDA) have approved FDCs to treat various conditions such as hypertension, tuberculosis, AIDS and diabetes to name a few. The pharmaceutical companies developing these FDCs protect the products from their competitors with the help of patents. Patents are a form of intellectual property, which are legal and institutional mechanisms to protect creations of mind. In recent years, there are instances of patents granted for FDCs by the USFDA. This study attempts to review issue of anti-diabetic FDCs and patents.

AB - Science driven therapeutics addresses only the diseases but does not provide cure and sometimes fails to meet the needs of patient. The pharmaceutical companies have, in recent years, started providing complementary products to improve the therapeutic value of the medicines. This is in the form of Fixed dose combination drugs (FDCs) The last couple of years have seen a trend in marketing of FDCs by pharmaceutical companies. Common focus of FDCs include anti-infectives, CNS, cardiovascular including hypertension and lipidemia, diabetes,contraceptives, HIV and respiratory. The United States Food and Drugs Administration (USFDA) have approved FDCs to treat various conditions such as hypertension, tuberculosis, AIDS and diabetes to name a few. The pharmaceutical companies developing these FDCs protect the products from their competitors with the help of patents. Patents are a form of intellectual property, which are legal and institutional mechanisms to protect creations of mind. In recent years, there are instances of patents granted for FDCs by the USFDA. This study attempts to review issue of anti-diabetic FDCs and patents.

UR - http://www.scopus.com/inward/record.url?scp=85044204513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044204513&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85044204513

VL - 50

SP - 12

EP - 16

JO - Pharma Times

JF - Pharma Times

SN - 0031-6849

IS - 1

ER -